Vivo Capital, LLC Avadel Pharmaceuticals PLC Call Options Transaction History
Vivo Capital, LLC
- $677 Million
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AVDL
# of Institutions
12Shares Held
7.03MCall Options Held
0Put Options Held
0-
Tri Locum Partners LP New York, NY1.19MShares$18.4 Million4.32% of portfolio
-
Bio Impact Capital LLC Cambridge, MA783KShares$12.1 Million1.77% of portfolio
-
Knoll Capital Management, LLC Miami, FL600KShares$9.28 Million5.7% of portfolio
-
Knott David M Jr Syosset, NY333KShares$5.15 Million1.87% of portfolio
-
Schulhoff & CO Inc137KShares$2.12 Million0.93% of portfolio
About AVADEL PHARMACEUTICALS PLC
- Ticker AVDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 60,581,300
- Market Cap $937M
- Description
- Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...